Interestingly, the anti-tumor and antimetastatic potential of desmopressin alone has also been shown in prostate cancer via downregulation of the urokinase-type plasminogen activator (uPA) and matrix metalloproteinase (MMP-2 and MMP-9) [125]. This evidence concerns the gene PLAU and Familial prostate cancer.